Ad www.AngelOne.in
FREE Account Opening + Zero AMC Fees* + MutualFund SIP1
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Ad www.AngelOne.in
Right Issue Status: Closed [23rd Jan 2024 to 13th Feb 2024]
Genpharmasec Limited is offering a rights issue of Rs 48.45 Cr. The subscription period for this rights issue will be from January 22, 2024 to February 9, 2024 and the company will issue 1 rights share for every fully paid-up 1 share held by the company on the record date of January 9, 2024. The face value of a share is Rs.1 per share and the issue price of the rights shares is fixed at Rs. 1.75 per share.
Stay connected with us to know more about Lloyds Genpharmasec Limited Right Issue Details 2023 including issue size, rights issue, payment terms and more.
The company proposes to utilize the net proceeds from the Issue towards funding the following objects:
| Genpharmasec Issue Details | Values |
|---|---|
| Category | RightIssue |
| Right Issue Issue Size (Shares) | 27.69 Cr Shares |
| Right Issue Issue Size (Amount) | ₹48.45 Cr |
| Face Value | ₹1 Per Equity Share |
| Right Issue - Issue Price | ₹1.75 per share |
| Right Issue Record Date | 9th Jan 2024 |
| Right Issue Entitlement | 1 Rights Equity Share(s) for every 1 fully paid-up Equity Shares held on Record Date |
| Right Issue Terms of payment | Full amount of Rs.1.75 per Equity Share is payable on application. |
| Listing At | BSE |
| BSE Code | 531592 |
| NSE Code |
In this section we have covered all important dates related to Genpharmasec Right Issue. Dates are updated as they are announced. The most noted dates are Right Issue start date and Right Issue end date, which one should use to participate in Right Issue.
| Right Issue Activity | Date |
|---|---|
| Right Issue Issue Open Date | 23rd Jan 2024 |
| Right Issue Issue Close Date | 13th Feb 2024 |
| Basis of Allotment Finalisation Date* | 16th Feb 2024 |
| Refunds Initiation* | 2nd Feb 2024 |
| Credit of Shares to Demat Account* | 21st Feb 2024 |
| Right Issue Listing Date* | 26th Feb 2024 |
* - Tentative Dates
Zerodha Trade@20
Genpharmasec Limited was founded in 1992 and was initially involved in the manufacture and trading of organic and inorganic chemicals, dyes and pigments. However, since 2018, the company has shifted its focus to the purchase, sale and distribution of various pharmaceutical, medical and drug preparations. The company has also decided to enter the securities market.
The company has entered into a partnership with Abbott Point of Care Corporation INC, based in the USA, to distribute their special diagnostic device called i-STAT 1 Analyzer. This device is used exclusively in intensive care units and hospitals for immediate test results. The i-STAT 1 Analyzer is lightweight, portable and easy to use. It utilises the advanced technology of the i-STAT test cassettes. Together they form the i-STAT system - a point-of-care testing platform that provides healthcare professionals with diagnostic information at the time and place it is needed.
Past performance and financial results of Genpharmasec .
Genpharmasec Limited's revenue decreased by -6.56% and profit after tax (PAT) rose by 637.15% between the financial year ending with March 31, 2023 and March 31, 2022.
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
| Assets | 19.88 | 21.65 | 27.82 |
| Revenue | 25.62 | 27.41 | 21.64 |
| Profit After Tax | 1.12 | -0.21 | 1.26 |
| Net Worth | 29.91 | 28.78 | 28.99 |
| Reserves and Surplus | 28.78 | 28.99 | |
| Total Borrowing | 3.08 | ||
| Amount in ₹ Crore | |||
The table below is live update of Right Issue bidding details from NSE and BSE.
Genpharmasec Right Issue Offer Document (Letter of Offer) >>Document
Genpharmasec Right Issue Offer Document (Letter of Offer) >>Genpharmasec Right Issue Red Herring Prospectus is not yet available.
Genpharmasec Right Issue Online Application (Registrar & Transfer Agent) >>Online Application
Genpharmasec Right Issue Online Application (Registrar & Transfer Agent) >>Genpharmasec Right Issue RTA information is not yet available.
Last Updated on 2024-02-16T04:33:01+00:00
